Story perspectives

Eli Lilly's Q1 Revenue Surges 45%, Stock Drops

5/2/2025

37 4

Summary

Story summary

Eli Lilly's Q1 2025 revenue reached $12.73 billion, marking a 45% increase, fueled by Mounjaro and Zepbound sales.
Despite exceeding earnings expectations, stock dropped 6.9% after CVS selected Novo Nordisk's Wegovy as its preferred weight-loss drug.
Lilly adjusted profit guidance downward due to a $1.57 billion charge from a cancer treatment deal, yet maintained a sales outlook of $58-$61 billion.
Mounjaro and Zepbound generated $3.84 billion and $2.31 billion, respectively, surpassing analyst predictions.

1 of 1

Story summary

Eli Lilly's Q1 2025 revenue reached $12.73 billion, marking a 45% increase, fueled by Mounjaro and Zepbound sales.
Despite exceeding earnings expectations, stock dropped 6.9% after CVS selected Novo Nordisk's Wegovy as its preferred weight-loss drug.
Lilly adjusted profit guidance downward due to a $1.57 billion charge from a cancer treatment deal, yet maintained a sales outlook of $58-$61 billion.
Mounjaro and Zepbound generated $3.84 billion and $2.31 billion, respectively, surpassing analyst predictions.